The expression of the chondroitin sulfate proteoglycan neuron-glial antigen 2 (NG2) has been demonstrated in association with rearrangement of the mixed lineage leukemia (MLL) gene in acute leukemia, but the frequency of NG2 expression in adult acute lymphoblastic leukemia (ALL) is yet unknown. We evaluated NG2 expression in 313 adult ALL patients by flow cytometry and simultaneously determined MLL rearrangement in 120 adult patients out of them with B-precursor ALL by reverse transcription-polymerase chain reaction and fluorescence in situ hybridization. A total of 57% of pro-B ALL, 2% of common ALL and 20% of pre-B ALL were NG2 positive, but NG2 was absent in T-ALL and mature B-ALL. In B-precursor ALL, NG2 expression was significantly associated with a CD10
Introduction
In hematopoietic malignancies chromosomal aberrations involving band 11q23 are frequent cytogenetic events, and an increasing number of translocation partners and various other structural abnormalities affecting 11q23 have been identified. 1 In adult acute lymphoblastic leukemia (ALL) with rearrangement of the mixed lineage leukemia gene (MLL), the translocation t(4;11)(q21;q23), is most frequently present. This translocation, like others involving 11q23, is associated with a CD24 À / CD65s + /CD15 + pro-B immunophenotype and an adverse clinical course. [2] [3] [4] [5] [6] [7] In t(4;11)(q21;q23), the MLL is juxtaposed to the AF-4 gene and this recombination can reliably be detected by reverse transcription-polymerase chain reaction (RT-PCR). 8 As MLL rearrangement indicates a dismal prognosis and recent data suggest that an intensified postremission therapy improves outcome in adult patients with t(4;11)(q21;q23), identification of these patients is important to guide therapeutic decisions. 8, 9 In an effort to identify cell-surface antigens of hematopoietic precursor and stromal cells, the monoclonal antibody (MoAb) 7.1 was generated by immunization with a human marrow stromal cell line. This MoAb recognizes a 220-240 kDa protein that shows a high degree of homology to the rat neuron-glial antigen 2 (NG2) chondroitin sulfate proteoglycan. 10 NG2 has been first discovered in the mammalian central nervous system, and it is assumed that the majority of NG2-positive cells within the central nervous system are oligodendrocyte progenitors. 11 In human leukemia, NG2 expression was found in close association with chromosomal aberrations involving 11q23 including t(4;11)(q21q23). Moreover, the presence of NG2 has predominantly been demonstrated in childhood pro-B ALL and in acute myeloid leukemia (AML) of M4/5 subtype. 10, [12] [13] [14] [15] [16] However, the expression of NG2 has been extensively studied in childhood acute leukemia, but there are scarce data on the pattern of NG2 expression in adult ALL. 15 To extend the knowledge of NG2 expression in adult ALL, we evaluated the pattern of NG2 expression by applying the MoAb 7.1 in a large series of adult ALL patients and compared the results with those of a screening for an MLL rearrangement as determined by RT-PCR or fluorescence in situ hybridization (FISH). Although it has been reported in a small series of pediatric patients that NG2 expression is associated with a CD24 À /CD65s + /CD15 + phenotype, this was not confirmed by a subsequent study encompassing a larger number of patients.
12,15
Thus, we determined the expression of NG2 together with various other surface antigens to evaluate precisely the immunophenotypic properties of NG2-positive ALL and the value of this novel antigen in predicting MLL rearrangement in adult ALL.
Material and methods

Immunophenotyping
Bone marrow (n ¼ 214) or peripheral blood (n ¼ 99) samples of 313 adult patients with newly diagnosed (n ¼ 299) or relapsed (n ¼ 14) ALL, sent to the central reference laboratory of the GMALL study group for diagnostic purposes, were evaluated for expression of NG2. Fresh samples of 220 patients and samples of 93 patients, thawed after storage in liquid nitrogen, were used for immunophenotypic analyses. Immunophenotyping was carried out as described previously in detail using a FACScan and Cell Quest software (Becton Dickinson, Heidelberg, Germany). 9 Commercially available fluorochrome MoAb conjugates, directed to B-, T-, myeloid-and progenitor-cell antigens, were used in dual-staining experiments. Expression of the NG2 molecule was determined in dual-staining experiments using the phycoerythrin-conjugated MoAb 7.1 (Beckman-Coulter, Krefeld, Germany). A cell-surface antigen was considered positive when 20% or more cells showed a fluorescence intensity greater than the negative control. Patients were assigned to the following subtypes according to previously published criteria of the EGIL group: pro-B ALL, common ALL, pre-B ALL, mature B-ALL, T-ALL. 17 Divergent from the EGIL classification, we considered a pro-B subtype in patients with or without expression of CD24. Additionally, the diagnosis pre-B ALL was made without taking CD10 expression into account. However, intracytoplasmatic (cy) expression of IgM (at least 10% of cyIgM-positive cells) was always required for the diagnosis of a pre-B ALL.
Detection of MLL-AF4 transcripts by RT-PCR
A total of 120 patients were evaluated for the presence of MLL-AF4 transcripts by RT-PCR. The following oligonucleotides were used (5 0 -3 0 ): 4A, TGCTGGAATGTGCTGATGCCACTG; 11A, TCCCGCCTCAGCCACCTACTAC; 4B, GAGGGAGGCTTCTCT-GGGGTTTGT; 11B, AAGAAGTTCCCAAAACCACTCCTAGTG.
Isolation of total RNA was carried out using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) in case of 5-8 Â 10 6 mononucleated cells, or the Invisorb RNA Kit II (Invitek, Berlin, Germany) in case of less than 5 Â 10 6 mononucleated cells, following the manufacturer's conditions. RT-PCR was performed as follows: 100-500 ng of total RNA was reverse transcribed using the First-Strand cDNA Synthesis Kit (Amersham Pharmacia Biotech, Freiburg, Germany) with 650 nM primer 4A following the manufacturer's protocol (final volume 15 ml). The first PCR reaction mix contained 7 ml RT reaction mix, 2.5 U Taq polymerase (Amersham Pharmacia Biotech, Freiburg, Germany) and 400 nM primer 4A and 11A, respectively (final volume 25 ml). Cycling conditions in the first PCR were as follows: denaturation for 1 min at 951C, 25 cycles for 10 s at 951C, for 20 s at 621C (annealing), and for 1 min at 721C, final cooling to 41C. The first PCR reaction mix was diluted 10-fold and 5 ml of the dilution was used in the second PCR with 1.25 U PfuTurbo polymerase (Stratagene, Amsterdam, Netherlands), 400 nM primer 4B and 11B, respectively, 200 nM dNTPs and PfuTurbo reaction buffer (final volume 25 ml). Cycling conditions in the second PCR were the same as in the first PCR except for 30 cycles and an annealing temperature 661C. Each RNA sample underwent a control RT-PCR amplifying a segment from the human ABL gene to ensure RNA quality as described previously. 18 Each RT-PCR included a previously tested MLL-AF4-mRNA-positive patient sample as a positive control. Aliquots of the PCR reaction mixes were analyzed on a 1% agarose gel and visualized under UV illumination after ethidium bromide staining. The size of the PCR products ranged from approximately 300 to 600 bp.
Cytogenetic analyses and FISH
Chromosomes were prepared and G-banded as previously described in detail, and results were classified according to the International System for Human Cytogenetic Nomenclature. 19, 20 FISH was carried out on fixed cells as described using commercially available probes which were located 5 0 and 3 0 of the typical breakpoint region of the MLL gene and directly labeled in two different colors (VYSIS Inc., Downers Grove, USA). 21 The hybridization signal patterns of at least 200 nuclei were scored in each case. An MLL rearrangement was indicated by separation of the 5 0 and 3 0 signals. A cutoff value for falsepositive nuclei was set at 10%.
Statistical analyses
Statistical comparisons were performed by using Fisher's exact or Mann-Whitney test, which ever was appropriate. Differences were regarded as significant at a P-valueo0.05. The calculations were performed with a commercially available software package (GraphPad Software Inc., San Diego, USA).
Results
Patients characteristics and expression of NG2 in ALL subgroups
Using the MoAb 7.1 we found NG2 expression in 73 of 313 (23%) adult patients with ALL. Comparison between NG2-positive and NG2-negative patients revealed no difference concerning the median age, but there were significant differences with respect to sex and the initial WBC: among females, the percentage of NG2-positive patients was higher as compared to males (33 vs 16%, respectively), and the median WBC at presentation was higher among NG2-positive patients compared to NG2-negative patients (140 vs 14.1/nl, respectively) ( Table 1 ). NG2 expression was most frequently present in patients with pro-B ALL: 62 of 109 patients (57%) were NG2 positive, whereas two of 107 patients with common ALL showed NG2 expression, only. Among patients with pre-B ALL there was a remarkable high number of NG2-positive patients: nine of 46 (20%) were NG2-positive (Table 1) . Interestingly, all nine patients with NG2-positive pre-B ALL were CD10 negative, whereas 32 of 37 (86%) of patients with NG2-negative pre-B ALL were CD10 positive (Po0.05, Fisher's exact test; data not shown). All 46 pre-B-ALL patients, including CD10-negative patients, showed unequivocal cyIgM expression and were thus assigned to the pre-B-ALL subgroup. Patients with mature B-ALL (n ¼ 7), as well as all patients with T-lineage ALL (n ¼ 44, including nine patients with pre-T ALL) did not show NG2 expression (Table 1) .
Comparative immunophenotype of NG2-positive and NG2-negative ALL
The expression of various B-, myeloid-, and progenitor-cell antigens was evaluated in patients with B-precursor ALL (pro-B ALL, common ALL, pre-B ALL) and results were compared between NG2-positive and NG2-negative patients. Patients with NG2-positive ALL were more frequently positive for the myeloid antigens CD65s and CD15 when compared to NG2-negative patients. Coexpression of the myeloid antigens CD13 and CD33, expression CD24 and CD10, and, remarkably, expression of the progenitor-cell antigen CD34 was more frequent in NG2-negative patients when compared to NG2-positive patients ( Fig. 1 ). In addition, we observed a higher frequency of CD34 expression in patients without MLL rearrangement compared to patients with MLL rearrangement (84 vs 43% were CD34 positive, respectively; data not shown). All these differences reached statistical significance (Po0.01). The frequency of expression of the stem cell factor receptor (CD117), which was positive in one patient with pro-B ALL, only, as well as expression of CD22 (either intracytoplasmatic or cell surface expression) did not show significant differences in NG2-positive compared to NG2-negative patients (Fig. 1) . Similar results were obtained when the analysis was restricted to patients with pro-B ALL (data not shown).
Correlation of NG2 expression with MLL rearrangement and detailed immunophenotypic characteristics of patients with discordant results
In all, 120 patients were evaluated by RT-PCR for the presence of MLL-AF4 rearrangement (pro-B ALL: n ¼ 105, common ALL: n ¼ 2; pre-B ALL: n ¼ 13) and results were correlated to NG2 expression. Of 72 (89%) MLL-AF4-positive patients, 64 showed NG2 expression, compared to nine of 48 (19%) MLL-AF4-negative patients who were NG2 positive ( Table 2 ).
In seven of nine NG2-positive patients who were tested negative for MLL rearrangement by RT-PCR, an additional cell sample was available to perform FISH (Table 3) . Four of these seven NG2-positive patients revealed MLL-rearrangement as determined by FISH: two patients showed a separation of 5 0 and 3 0 signals confirming a translocation involving MLL (pts. 1 and 2; Table 3 ) and in two other patients there was a single 3 0 signal together with two 5 0 signals indicating a deletion within the 3 0 region of MLL (pts. 3 and 4; Table 3 ). All, but one, of these four patients presented with hyperleukocytosis and all four patients showed immunophenotypic characteristics that are compatible with MLL rearrangement: attenuated or absent expression of CD24 in all patients; no CD10 expression in three patients (Table 3 ). In the remaining three patients, who were additionally analyzed by FISH, we could not detect an MLL rearrangement (pts. 5-7). Results of G-banding were available in one of these three patients (pt. 6) disclosing dic(9;20)(p11;q11), an aberration that has been described in B-precursor ALL. 19 Two of these patients had no hyperleukocytosis at presentation (one patient without data) and the immunophenotypic characteristics were not highly indicative of an MLL rearrangement: one patient had a CD24-negative pro-B ALL, but was positive for CD13 and CD33 (pt. 5); two patients showed weak or absent expression of CD10, but lacked further immunophenotypic characteristics such as attenuated/absent expression of CD24 or positivity for CD15/CD65s (pts. 6 and 7) ( Table 3) .
Eight patients with detectable MLL-AF4 transcripts were found to be NG2 negative ( Table 2 ). Two of these eight patients had a hyperleukocytosis at presentation ( Table 4 ). All of these eight patients had a CD10-negative pro-B ALL (n ¼ 6) or CD10-negative pre-B ALL (n ¼ 2). Five patients had immunophenotypic characteristics, which are suggestive of an MLL rearrangement such as absent CD24 expression (pts. 3-5) or coexpression of CD65s/ CD15 (pts. 1, 3 and 8). However, two patients had none of these features (pts. 2 and 7) and another patient (pt. 6) had a weak CD24 expression, but also showed coexpression of CD13 (Table 4) . 
Figure 1
Immunophenotype of NG2-positive and NG2-negative B-precursor ALL.
NG2 in adult ALL with MLL rearrangement S Schwartz et al Sensitivity, specificity and positive predictive value of NG2 compared to other surface antigens in predicting MLL rearrangement
We calculated the sensitivity, specificity and positive predictive value of NG2 compared to various surface markers of relevance (CD10, CD24, CD65s, CD15, CD33 and CD13) in predicting MLL rearrangement. Data of 120 patients with B-precursor ALL were available for this analysis. NG2 showed a sensitivity of 0.89 in predicting MLL rearrangement (Table 5 ). This result was higher when compared to other antigens except for CD10, CD33 and CD13, which all showed a sensitivity of 0.99. The numbers of patients are given. The percentage of positive blasts is displayed for each antigen investigated. The percentages and absolute numbers of patients positive (+) or negative (À) for the respective antigen are displayed.
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However, specificities of CD10, CD33 and CD13 were much lower (all r0.27) compared to a specificity of 0.89 for NG2. The positive predictive value of NG2 in predicting MLL rearrangement was 0.93, which was lower compared to CD65s (0.96), only. However, the sensitivity of CD65s was 0.591 and lower compared to a sensitivity of 0.89 for NG2 (Table 5) ), and we identified seven patients disclosing at least one of these immunophenotypic characteristics. One patient with CD10-positive ALL lacked CD24 expression as the only immunophenotypic feature suggesting the presence of MLL rearrangement. Four patients had a CD24 + /CD65s À /CD15 À immunophenotype with an attenuated, but clearcut positive, staining for CD24 and a lack of CD10 expression. Two patients showed coexpression of CD13 or CD33. Both of these patients had CD10-negative ALL with synchronous coexpression of CD15 and CD65s and one of these two patients was in addition CD24 negative (data not shown). All these seven patients with an equivocal immunophenotype not clearly suggesting the presence of MLL rearrangement showed a clearcut staining for NG2 (at least 50% of leukemic blasts were NG2 positive).
Finally, we determined the marker panel that predicted MLL rearrangement with the highest accuracy. NG2 expression together with coexpression of CD65s and/or CD15 yielded the best result. Of 120 patients, 49 showed this immunophenotype and all these patients had MLL rearrangement. All other marker combinations were found in lower number of patients or were also present in patients without MLL rearrangement (data not shown).
Discussion
In the present study, we determined the expression of the human homologue of rat NG2 in the largest series of adult ALL patients investigated to date. Simultaneously, we obtained informations on the immunophenotype and the presence of MLL rearrangement by RT-PCR and FISH in a substantial number of patients with B-precursor ALL. This appears to be of interest for various reasons. First, previously published studies found a clear association of NG2 expression with MLL rearrangement, but these studies were restricted almost entirely to pediatric patients and data of 16 adult ALL patients are available, only.
12,15,16
Therefore, we were interested to extend the knowledge of this novel antigen, which shows the expression in hematopoiesis restricted to malignant cells, and to evaluate at a larger basis whether NG2 occurs strictly in association with MLL rearrangement. Second, it is recognized that ALL with MLL rearrangement frequently exhibits a distinct immunophenotype (coexpression of CD65s/CD15, negativity of CD24 and CD10). 2, 3, 9 Likewise, an association of NG2 expression with these typical immunophenotypic features has been demonstrated in a small series of nine pediatric patients. 12 However, except for a lack of CD10 expression, this was not supported by a subsequent study investigating a larger number of pediatric patients, which failed to show an association of NG2 with a CD65s + /CD15 + /CD24
À immunophenotype in ALL. 15 Third, a direct comparison between the aforementioned, well-described immunophenotypic features and NG2 expression with respect to their predictive value of an MLL rearrangement in ALL has yet been performed in a smaller series of infants, only. 16 As the frequency of MLL rearrangement might be underestimated by conventional karyotyping and as more sensitive techniques, such as PCR, FISH or blot analysis, are not always readily available, a more rapid and easy recognition of MLL rearrangement by means of flow cytometry would be useful for early therapeutic decisions in high-risk ALL patients. Therefore, we were particularly interested to evaluate whether NG2 contributes to a reliable prediction of MLL rearrangement in adult ALL.
As expected, we found a high frequency of 57% of NG2 positivity in patients with pro-B ALL confirming that NG2 expression is closely linked to an immature B phenotype in ALL. The frequency of NG2 expression among patients with pro-B LL in our series, however, differs slightly compared to results from a previous report (57 vs 62% of patients with pro-B-ALL NG2 positive, respectively), and this appears to be because of the varying number of patients and the high percentage of childhood ALL investigated previously. 15 We found expression of NG2 in a striking high frequency (20%) among patients with pre-B ALL. This extends observations in previous studies, who found NG2 expression occasionally in patients with pre-B ALL and underlines that NG2 expression is not restricted to an immature nature of leukemic blasts.
12, 15, 16 Interestingly, all nine patients with NG2-positive pre-B ALL in the present series showed a rearrangement of MLL: eight patients had MLL-AF4 transcripts and one patient showed a deletion within the 3 0 region of MLL. This parallels findings from the European Union Concerted Action Workshop on 11q23: among ALL patients with t(4;11)(q21;q23) 15% (26/173) were classified as pre-B ALL and del(11)(q23) has also been demonstrated in pre-B-ALL. 22, 23 Thus, the close association between NG2 positivity and the presence of MLL rearrangement in these nine patients with pre-B-ALL strongly suggest that these patients are at an increased risk for treatment failure. The fact that none of our patients with mature B-ALL and T-ALL showed NG2 expression corresponds to previous findings.
12,15 NG2 expression has not yet been observed in mature B-ALL, but has been described in a single patient with T-ALL and t(11;19)(q23;p13).
12
In contrast to a previous report investigating a large number of patients with ALL, 15 we found a clearcut association of immunophenotypic features that are typically associated with MLL rearrangement in ALL (coexpression of CD65s or CD15, negativity of CD24) with NG2 expression in patients with Bprecursor ALL. Moreover, coexpression of CD13 or CD33 is unlikely to occur in NG2-positive ALL as demonstrated in our and in a previous series of patients. 15 This raises the question whether MLL rearrangement might reliably be predicted by the immunophenotype. In recent studies, which were almost exclusively done in pediatric and infant ALL, NG2 showed a sensitivity approaching 90% and a specificity and positive predictive value of 100% in predicting MLL rearrangement, but the number of patients investigated were smaller than in the present study. In particular, the number of patients without MLL rearrangement were very small or not reported. 15, 16 Our analysis of the largest cohort of patients investigated thus far confirms that with respect to sensitivity and positive predictive value NG2 appears to be a powerful marker in recognizing MLL rearrangement not only in pediatric but also in adult ALL. In contrast to previous reports, our data clearly show that NG2 might also be expressed in ALL without detectable aberrations involving 11q23, as well as in ALL exhibiting other chromosomal abnormalities such as a rare occurring dic (9;20) . Thus, NG2 is not an entirely specific marker in predicting a rearrangement of MLL. However, NG2 expression, together with a coexpression of CD65s + /CD15 + , identifies with a 100% accuracy MLL NG2 in adult ALL with MLL rearrangement S Schwartz et al rearrangement in adult ALL, as demonstrated by the present study. Thus, at least in a subset of ALL, the immunophenotypic profile of leukemic blasts reliably predicts MLL rearrangement. Unexpectedly, we observed a significant lower frequency of CD34 expression in NG2-positive compared to NG2-negative patients with B-precursor ALL. Similarly, we found a low frequency of CD34 expression in patients with MLL rearrangement compared to patients without MLL rearrangement. This finding is difficult to explain and contrasts most recent findings in infant ALL. 16 Leukemic blasts in pro-B ALL with MLL rearrangement are commonly regarded to be derived from a very immature precursor cell and this view is supported by a recently published study evaluating gene expression profiles. 24 Expression of CD34 has been found at a lower frequency in CD10 À compared to CD10 + B-precursor ALL, 25, 26 but this is not supported by a previous study encompassing a large number of pediatric patients. 27 Recently, in two large series of adult patients expression of CD34 has been shown to be significantly correlated with t(9;22). 26, 28 Thus, it appears likely that patients with t(9;22) were assigned to the NG2-negative group contributing at least in part to the observed inverse correlation of NG2 with CD34 in the present study, but this has not been investigated in more detail. Interestingly, a similar observation has been recently made in patients with acute myeloid leukemia. Wuchter et al 15 found NG2 expression associated with a more mature immunophenotype, as characterized by CD34
À and various other antigens, in patients with AML. The inverse correlation of NG2 and MLL rearrangement with CD34 expression and our observation of NG2 expression and MLL rearrangement in cyIgM-positive pre-B ALL is a striking finding suggesting two different explanations: the leukemic cells are indeed derived from a very immature B-precursor cell but do not retain their immature features during the multistep process of leukemogenesis or they might be derived from a more committed or mature B-precursor cell. Recently, MoAbs recognizing different epitopes of the pre-B-cell receptor have been tested in ALL and a new classification of B-lineage ALL based on the expression of components of the pre-B-cell receptor has been proposed. 29 It appears attractive to test this novel classification in more detail and in comparison with established marker panels, as this might give further insight into the immunophenotypic diversity of B-precursor ALL.
The reason why expression of NG2 is found in acute leukemia remains obscure. NG2 is physiologically expressed in the CNS and various other tissues, but cells of hematopoietic origin are negative for this antigen. 10, 11 It has been speculated that continued expression of NG2 at an early stage of development results in surface expression of this antigen or disruption of the MLL gene may be involved in a process leading to an aberrant de novo expression of NG2, but neither hypothesis has been proven. 10, 15 The close association of NG2 expression with MLL rearrangement supports the latter theory. However, as demonstrated in this study, NG2 expression might occur in acute leukemia without MLL rearrangement, suggesting that aberrant expression of this antigen is mediated by other mechanisms in at least a small number of patients.
In conclusion, NG2 expression reliably detects MLL rearrangement in a subset of adult ALL with a CD65s + /CD15 + immunophenotype and is at least as powerful as other established surface antigens in predicting MLL rearrangement in ALL. Thus, the MoAb 7.1 should be incorporated into routine marker panels used in the diagnosis of ALL to facilitate identification of poor-prognosis patients. In our view, a broad immunophenotypic approach should not lead to omission of subsequent karyotype/molecular analyses, as aberrations affecting the chromosomal region 11q23 (eg deletion of 11q23) have been reported in association with a favorable clinical course. 30 In addition, NG2 expression might rarely occur in conjunction with other karyotype abnormalities not affecting 11q23 such as dicentric (9;20) , a rarely observed abnormality in ALL not obviously associated with an adverse clinical course. 19, 31 Finally, it has been recently shown that monitoring of minimal residual disease is useful in the prediction of the prognosis in patients with ALL. 32, 33 As NG2 is not expressed on normal hematopoietic cells, this antigen appears to be an interesting target for monitoring minimal residual disease and ongoing studies by our group and others will evaluate the value of this antigen in this diagnostic setting.
